The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia
Open accessAbstract
The antifungal efficacy, safety, and pharmacokinetics of posaconazole (SCH 56592) (POC) were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Antifungal therapy consisted of POC at 2, 6, and 20 mg/kg of body weight per os; itraconazole (ITC) at 2, 6, and 20 mg/kg per os; or amphotericin B (AMB) at 1 mg/kg intravenously. Rabbits treated with POC showed a significant improvement in survival and significant reductions in pulmonary infarct scores, total lung weights, numbers of pulmonary CFU per gram, numbers of computerized-tomography-monitored pulmonary lesions, and levels of galactomannan antigenemia. AMB and POC had comparable therapeutic efficacies by all parameters. By comparison, animals treated with ITC had no significant changes in outcome variables in comparison to those of untreated controls (UC). Rabbits receiving prophylactic POC at all dosages showed a significant reduction in infarct scores, total lung weights, and organism clearance from lung tissue in comparison to results for UC ( P < 0.01). There was dosage-dependent microbiological clearance of A. fumigatus from lung tissue in response to POC. Serum creatinine levels were greater ( P < 0.01) in AMB-treated animals than in UC and POC- or ITC-treated rabbits. There was no elevation of serum hepatic transaminase levels in POC- or ITC-treated rabbits. The pharmacokinetics of POC and ITC in plasma demonstrated dose dependency after multiple dosing. The 2-, 6-, and 20-mg/kg dosages of POC maintained plasma drug levels above the MICs for the entire 24-h dosing interval. In summary, POC at ≥6 mg/kg/day per os generated sustained concentrations in plasma of ≥1 μg/ml that were as effective in the treatment and prevention of invasive pulmonary aspergillosis as AMB at 1 mg/kg/day and more effective than cyclodextrin ITC at ≥6 mg/kg/day per os in persistently neutropenic rabbits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A., McGinnis, M. R., Menezes, P., Messer, S. A., Nelson, P. W., et al. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.1.139-143.1997 · Cited by 228 · cited 2×
“fumigatus have been reported as being relatively lower than those of ITC (12, 34).”
BackgroundMethodSelf-citation
Cited by
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Self-citationWalsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Self-citationLimper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Maertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., Wilmer, A., Verhaegen, J., Boogaerts, M., & Eldere, J. V. (2005) · Clinical Infectious Diseases · doi:10.1086/496927 · Cited by 592
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Marr, K. A., Balajee, S. A., McLaughlin, L., Tabouret, M., Bentsen, C., & Walsh, T. J. (2004) · The Journal of Infectious Diseases · doi:10.1086/422009 · Cited by 483
Self-citationDetection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Mennink-Kersten, M. A., Donnelly, J. P., & Verweij, P. E. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01045-x · Cited by 482
Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay
Marr, K. A., Laverdiere, M., Gugel, A., & Leisenring, W. (2005) · Clinical Infectious Diseases · doi:10.1086/429921 · Cited by 471
Segal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
Self-citationPharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Pfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Self-citationPosaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Walsh, T. J., Petraitis, V., Petraitiene, R., Field‐Ridley, A., Sutton, D., Ghannoum, M., Sein, T., Schaufele, R., Peter, J., Bacher, J., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 253
Self-citationEspinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G., & Walsh, T. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3204-3208.2002 · Cited by 203
“Peak levels in plasma that were below the MIC and MFC results in this study correlated with in vivo response in experimental pulmonary aspergillosis caused by isolate 8 (23).”
ResultSelf-citationSegal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168
Self-citationAntifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
Animal Models for Studying Triazole Resistance in Aspergillus fumigatus
Lewis, R. E., & Verweij, P. E. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix222 · Cited by 13
Metadata
- Authors
- Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., & Walsh, T. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2001-03
- Volume
- 45
- Issue
- 3
- Pages
- 857-869
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2091637502
- Cited by
- 179
- References
- 4
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.